Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals Inc (KALV) is a clinical-stage biopharmaceutical company advancing novel protease inhibitors for rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Our curated collection offers immediate access to KALV's latest press releases, including progress on oral plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema therapies. Track updates across all development phases – from preclinical research to late-stage trials – while staying informed about partnership announcements and financial disclosures.
Key coverage areas include clinical trial results, FDA communications, intellectual property developments, and scientific presentations. The resource is particularly valuable for monitoring KALV's Factor XIIa inhibitor program and comparative effectiveness data against existing therapies.
Bookmark this page for real-time updates on KalVista's innovative pipeline and regulatory progress. For comprehensive tracking of this clinical-stage innovator's journey in protease inhibition therapeutics, we recommend checking back regularly.
KalVista Pharmaceuticals (Nasdaq: KALV) reported third-quarter 2025 results and an operational update focused on the commercial launch of EKTERLY. The company recognized $13.7M in net product revenue for Q3 and received 937 patient start forms through October with 423 unique prescribers activated. EKTERLY launched in Germany and received approvals in the EU, Switzerland and Australia. KalVista closed a $144M convertible note and held $309.2M in cash and marketable securities as of September 30, 2025.
R&D declined to $12.0M and SG&A rose to $46.5M in Q3 2025, reflecting commercialization activity.
KalVista (Nasdaq: KALV) presented new patient satisfaction and pediatric data for EKTERLY (sebetralstat) at ACAAI 2025 on November 6, 2025.
Key findings: in KONFIDENT-S, 1,089 attacks treated by patients who switched from injectable on-demand therapies had a median satisfaction score of 2 on a −3 to 3 Likert scale, with 84% of attacks rated satisfied/very/extremely satisfied. Interim KONFIDENT-KID results (as of June 6, 2025) in 26 children covering 65 attacks showed mean 0.8 attacks/month, median treatment administration time by caregiver/patient 30 minutes, median time to symptom relief in the 150 mg cohort 1.5 hours, and no serious or treatment-related adverse events reported.
Complementary Delphi and survey data highlighted barriers to injectable care (86% delay rate) and strong patient preference for oral on-demand treatment (89%).
KalVista Pharmaceuticals (Nasdaq: KALV) will participate in fireside chats at two investor conferences in November 2025.
Events and times: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:40 a.m. EST, and Jefferies Global Healthcare Conference (London) on Wednesday, November 19, 2025 at 1:30 p.m. GMT.
Live audio webcasts will be available on the company Investors page at www.ir.kalvista.com/event-calendar, with archived replays posted approximately two hours after each event concludes.
KalVista Pharmaceuticals (Nasdaq: KALV) will host a third quarter 2025 financial results conference call and webcast on Tuesday, November 11, 2025 at 8:30 a.m. ET. The company will review Q3 results and provide an operational update.
The live audio webcast will be available on the Investors section at www.ir.kalvista.com/event-calendar. An archived replay will be posted approximately two hours after the event.
KalVista Pharmaceuticals (Nasdaq: KALV) will present new data for EKTERLY® (sebetralstat) at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.
The company has one late‑breaking oral abstract—interim KONFIDENT‑KID pediatric (ages 2–11) on‑demand treatment results—scheduled for Nov 8 at 5:33 PM ET, plus three poster presentations on Nov 7 covering patient satisfaction, a Delphi consensus on treatment barriers, and patient‑physician alignment. Presentation locations and times are provided for each session. Links to all presentations will be posted on KalVista’s Publications page on Nov 6, 2025.
KalVista Pharmaceuticals (Nasdaq: KALV) presented new European data showing oral EKTERLY (sebetralstat) rapidly halts hereditary angioedema (HAE) attacks and addresses barriers tied to injectable on-demand therapies. Key clinical findings: a median 20 minutes to end of attack progression across KONFIDENT and KONFIDENT-S, and KONFIDENT-S interim data (69 participants, 999 treated attacks) reporting a median time to treatment of 16 minutes (10 minutes in adolescents) and median 1.6 hours to symptom relief. A German patient survey (49 respondents) found a mean time to treatment of 3.9 hours, only 18% treated within 1 hour, and 53% experienced injection-site reactions, highlighting uptake barriers for injectables. EKTERLY is approved in the European Union with a planned Germany launch this quarter and additional European launches in 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) appointed Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. Both executives bring 25+ years of industry experience to support the global launch of EKTERLY. Mr. Arif’s background spans technical operations, manufacturing, and global launches; Ms. Aspesi’s background spans HR leadership across biopharma and healthcare.
Each new hire will receive an inducement option to purchase 100,000 shares (grant date October 8, 2025), exercise price equal to the Nasdaq closing price on the grant date, vesting over four years (25% at one year, then monthly), and a 10-year term.
KalVista Pharmaceuticals (Nasdaq: KALV) announced on October 3, 2025 that its compensation committee granted inducement stock options to two newly hired employees totaling 30,000 shares on October 1, 2025.
The options’ exercise price equals the closing price on the first trading day with a reported close following the grant date. Vesting: 25% at one year, then monthly vesting over the next three years, subject to continued service. Each option carries a 10-year term and is governed by KalVista’s Inducement Equity Incentive Plan and stock option agreements. Grants comply with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Bethany L. Sensenig to its Board of Directors and Audit Committee, effective October 1, 2025. Ms. Sensenig brings over 20 years of leadership experience in finance, corporate strategy, and commercial operations to KalVista.
Currently serving as CFO and Head of Operations at Radius Health, Sensenig's extensive experience includes roles as CFO and Interim CEO at 9 Meters Biopharma, and a 13-year tenure at Biogen where she managed revenue exceeding $1B across 30 countries. The appointment comes as KalVista continues the global commercialization of EKTERLY, their first-in-class oral on-demand therapy for hereditary angioedema (HAE).
KalVista Pharmaceuticals (NASDAQ:KALV) announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress in Düsseldorf, Germany, scheduled for October 2-4, 2025.
The presentations will focus on various aspects of EKTERLY® (sebetralstat) in treating Hereditary Angioedema (HAE) attacks. Key topics include time to end of HAE attack progression, effectiveness in European participants, treatment of mucosal attacks, impact on patient anxiety, treatment efficacy in combination with berotralstat, and barriers to timely treatment in German patients.
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
